Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.
Gastrointestinal Stromal Tumors
DRUG: Imatinib mesylate|DRUG: Imatinib mesylate|DRUG: Imatinib mesylate
Evaluation of Lesions for Progression or Response Via RECIST Criteria, Every 3 months
The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.